🇪🇺 Saquinavir (Invirase®) in European Union

EMA authorised Saquinavir (Invirase®) on 3 October 1996

Marketing authorisation

EMA — authorised 3 October 1996

  • Application: EMEA/H/C/000113
  • Marketing authorisation holder: Roche Registration GmbH
  • Local brand name: Invirase
  • Indication: Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.
  • Status: withdrawn

Read official source →

Saquinavir (Invirase®) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in European Union

Frequently asked questions

Is Saquinavir (Invirase®) approved in European Union?

Yes. EMA authorised it on 3 October 1996.

Who is the marketing authorisation holder for Saquinavir (Invirase®) in European Union?

Roche Registration GmbH holds the EU marketing authorisation.